Researchers at Tel Aviv University used a portable brain activity-measuring device to detect cognitive decline in older people
News
Jazz Pharmaceuticals’ epilepsy drug advances into phase 3 trial
Epidiolex may ease symptoms associated with Doose syndrome, a rarer type of childhood-onset epilepsy
NHS leaders urge government to act or risk public health emergency
Senior public health figures take unusual step of warning government about energy costs
Positive appraisal for Eisai’s Kisplyx in combination with MSD’s Keytruda
NICE approval is for first-line treatment of intermediate and advanced renal cell carcinoma
New drug application accepted by FDA for GSK’s momelotinib
Therapy for the treatment of myelofibrosis has received significant results from phase 3 trial
Chiesi’s Trimbow recommended for use within NHS Scotland
The SMC approval brings much-needed boost to asthma sufferers across Scotland
Sanofi provides update on amcenestrant
The company’s clinical development programme is to be discontinued following a recent evaluation
LifeArc and Great Ormond Street Hospital charity award £1.3m to tackle diseases
Funds will allow researchers to focus on improving the lives of children with rare conditions
Lynparza in combination with abiraterone granted priority review in US
New therapy is aimed at patients with metastatic castration-resistant prostate cancer
Evonetix commences access programme for synthesised DNA
Researchers are invited to apply to receive DNA that has been synthesised using Evonetix’s platform
Santen launches Ducressa for post-cataract surgery
Treatment involves a combination of levofloxacin and dexamethasone for use after cataract surgery
MHRA authorises Moderna’s omicron-containing bivalent booster
Study results show the candidate has demonstrated significantly higher antibodies against Omicron
NICE recommendation expands patient eligibility for AbbVie’s Ozurdex
Treatment becomes an option for treating visual impairment caused by diabetic macular oedema, regardless of lens status
MHRA grants marketing authorisation for Novartis’ Pluvicto
Radioligand therapy involves patients with advanced prostate cancer in Great Britain
Medicines Discovery Catapult and Zeiss join forces
Partnership will focus on driving the application of microscopy in drug discovery
